What is Evestra?
Evestra operates at the intersection of advanced pharmacology and specialized patient care, focusing on high-impact therapeutic areas including fertility control, endometriosis, and hormone replacement therapy. As a privately held organization, the company maintains a diverse pipeline that spans both pre-clinical and clinical-stage assets. Their commitment to addressing unmet medical needs through next-generation healthcare technologies has established them as a critical player in the biopharmaceutical sector. By targeting specific conditions such as overactive bladder and complex oncological profiles, Evestra demonstrates a sophisticated approach to drug development that prioritizes long-term patient outcomes and global health improvements.
How much funding has Evestra raised?
Evestra has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Evestra
PPP
Public-Private Partnership
What's next for Evestra?
With the recent infusion of capital, Evestra is poised to transition its most promising clinical-stage candidates toward regulatory milestones and potential commercialization. The strategic focus will likely remain on scaling its research and development infrastructure to support the advancement of its proprietary pipeline. As the company navigates the complexities of late-stage clinical trials, the management team is expected to prioritize operational efficiency and the expansion of its therapeutic portfolio. This phase of growth is critical for Evestra as it seeks to validate its innovative technologies within the broader medical community, ultimately aiming to deliver transformative solutions for women's health on a global scale.
See full Evestra company page
